TY  - JOUR
AU  - Isebia, Khrystany T
AU  - de Jong, Anouk C
AU  - van Dessel, Lisanne F
AU  - de Weerd, Vanja
AU  - Beaufort, Corine
AU  - Helmijr, Jean
AU  - Nakauma-González, José Alberto
AU  - van Riet, Job
AU  - Hamberg, Paul
AU  - Vis, Daniel
AU  - van der Heijden, Michiel S
AU  - Beije, Nick
AU  - Lolkema, Martijn P
AU  - Deger, Teoman
AU  - Wilting, Saskia M
AU  - de Wit, Ronald
AU  - Jansen, Maurice P H M
AU  - Martens, John W M
TI  - Cell-free DNA aneuploidy score as a dynamic early response marker in prostate cancer.
JO  - Molecular oncology
VL  - nn
SN  - 1574-7891
CY  - Hoboken, NJ
PB  - John Wiley & Sons, Inc.
M1  - DKFZ-2025-00563
SP  - nn
PY  - 2025
N1  - epub
AB  - Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker for response evaluation in metastatic castration-resistant prostate cancer (mCRPC). The current study evaluated the modified fast aneuploidy screening test-sequencing system (mFast-SeqS), a quick, tumor-agnostic and affordable ctDNA assay that requires a small input of DNA, to generate a genome-wide aneuploidy (GWA) score in mCRPC patients, and correlated this to matched metastatic tumor biopsies. In this prospective multicenter study, GWA scores were evaluated from blood samples of 196 mCRPC patients prior to treatment (baseline) with taxanes (docetaxel and cabazitaxel) and androgen receptor signaling inhibitors (ARSI; abiraterone and enzalutamide), and from 74 mCRPC patients at an early timepoint during treatment (early timepoint; median 21 days). Z-scores per chromosome arm were tested for their association with tumor tissue genomic alterations. We found that a high tumor load in blood (GWAhigh) at baseline was associated with poor response to ARSI [HR: 2.63 (95
KW  - abiraterone (Other)
KW  - cabazitaxel (Other)
KW  - ctDNA (Other)
KW  - docetaxel (Other)
KW  - enzalutamide (Other)
KW  - prostate cancer (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40084488
DO  - DOI:10.1002/1878-0261.13797
UR  - https://inrepo02.dkfz.de/record/299826
ER  -